| Dilendra Haritha Weerasinghe, MD | |
|
21298 Olean Blvd, Port Charlotte, FL 33952-6705 | |
| (941) 629-1181 | |
| Not Available |
| Full Name | Dilendra Haritha Weerasinghe |
|---|---|
| Gender | Male |
| Speciality | Surgery |
| Location | 21298 Olean Blvd, Port Charlotte, Florida |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1710207352 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208600000X | Surgery | ME115020 (Florida) | Primary |
| Entity Name | University Of Florida Jacksonville Physicians, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1144276452 PECOS PAC ID: 9133025869 Enrollment ID: O20040128000786 |
News Archive
The October issue of the journal Anesthesiology contains a study reviewing potential adverse effects associated with the timing of a patient's heart surgery; but based on this study, there is no bad time of the day or week or year to have elective coronary artery bypass graft surgery.
The traditional device manufacturers used by doctors such as Welch Allyn, Keeler and Heine aren't digital. It means that they have an external light source (with a battery) and are used to look into the ears but the doctors can't capture the images.
In an effort to further individualize therapy and avoid over-treating patients, researchers at the Johns Hopkins Kimmel Cancer Center report a new study using PET scans has identified a biomarker that may accurately predict which patients with one type of HER2-positive breast cancer might best benefit from standalone HER2-targeted agents, without the need for standard chemotherapy.
Two perspective pieces from the New England Journal of Medicine examine West Virginia's new Medicaid program, which will allow 160,000 Medicaid beneficiaries - many of whom are parents of children enrolled in the program - to sign a "personal responsibility contract."
Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has accepted for standard review a new supplemental Biologics License Application for KEYTRUDA, Merck's anti-PD-1 therapy, as adjuvant therapy in the treatment of patients with resected, high-risk stage III melanoma and granted a Prescription Drug User Fee Act, or target action, date of February 16, 2019.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dilendra Haritha Weerasinghe, MD 11 Ocean Dr, Punta Gorda, FL 33950-5003 Ph: (941) 629-1181 | Dilendra Haritha Weerasinghe, MD 21298 Olean Blvd, Port Charlotte, FL 33952-6705 Ph: (941) 629-1181 |
News Archive
The October issue of the journal Anesthesiology contains a study reviewing potential adverse effects associated with the timing of a patient's heart surgery; but based on this study, there is no bad time of the day or week or year to have elective coronary artery bypass graft surgery.
The traditional device manufacturers used by doctors such as Welch Allyn, Keeler and Heine aren't digital. It means that they have an external light source (with a battery) and are used to look into the ears but the doctors can't capture the images.
In an effort to further individualize therapy and avoid over-treating patients, researchers at the Johns Hopkins Kimmel Cancer Center report a new study using PET scans has identified a biomarker that may accurately predict which patients with one type of HER2-positive breast cancer might best benefit from standalone HER2-targeted agents, without the need for standard chemotherapy.
Two perspective pieces from the New England Journal of Medicine examine West Virginia's new Medicaid program, which will allow 160,000 Medicaid beneficiaries - many of whom are parents of children enrolled in the program - to sign a "personal responsibility contract."
Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has accepted for standard review a new supplemental Biologics License Application for KEYTRUDA, Merck's anti-PD-1 therapy, as adjuvant therapy in the treatment of patients with resected, high-risk stage III melanoma and granted a Prescription Drug User Fee Act, or target action, date of February 16, 2019.
› Verified 2 days ago
Alvaro Ramon Bada, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 18308 Murdock Circle, #101, Port Charlotte, FL 33948 Phone: 941-255-0069 Fax: 941-255-0072 | |
Dr. John E Moenning, M.D. Surgery Medicare: Not Enrolled in Medicare Practice Location: 21450 Gibralter Dr, Port Charlotte, FL 33952 Phone: 941-766-9570 | |
Dr. Alvaro Miguel Bada, M.D. Surgery Medicare: May Accept Medicare Assignments Practice Location: 18308 Murdock Cir Unit 101, Port Charlotte, FL 33948 Phone: 941-255-0069 Fax: 941-255-0072 | |
Dr. Thomas Kartis Jr., M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 2327 Aaron St, Port Charlotte, FL 33952 Phone: 941-235-4400 Fax: 941-235-4402 | |
Dr. Alejandro Callejas, MD Surgery Medicare: Medicare Enrolled Practice Location: 2525 Harbor Blvd, 203, Port Charlotte, FL 33952 Phone: 941-627-9119 Fax: 941-627-3011 | |
Dr. Laura Ann Gruneiro, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 18316 Murdock Circle, Suite 107, Port Charlotte, FL 33948 Phone: 941-627-6700 Fax: 941-627-3300 | |
Dr. Matthew C Tufts, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 4245 Kings Hwy Unit A, General Surgery, Port Charlotte, FL 33980 Phone: 941-391-5102 |